Protagonist Therapeutics Inc (PTGX)
Solvency ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt-to-assets ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt-to-capital ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Debt-to-equity ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 |
| Financial leverage ratio | 1.10 | 1.14 | 1.14 | 1.12 | 1.06 | — | 1.09 | — | — | 1.16 | 1.16 | 1.15 | — | 1.13 | 1.13 | 1.15 | — | 1.28 | 1.34 | 2.15 |
Protagonist Therapeutics Inc has consistently maintained a Debt-to-assets ratio of 0.00, indicating that the company has not relied on debt to finance its assets during the periods analyzed. The Debt-to-capital ratio has also been low or unavailable (indicated by "\u2014") throughout the years, suggesting a minimal level of debt relative to the company's total capital.
The Debt-to-equity ratio has similarly been at 0.00 or unavailable, reflecting a balanced capital structure with little to no debt compared to equity. This signifies that the company has predominantly relied on equity financing rather than debt.
The Financial leverage ratio, which provides insight into the proportion of assets financed by debt, shows values below 1.5 for most periods analyzed. The decrease in the ratio over time indicates a lower reliance on debt to fund the company's operations and investments, contributing to a more stable and less leveraged financial position.
Overall, the solvency ratios suggest that Protagonist Therapeutics Inc has maintained a strong financial position with a conservative approach to debt management, minimizing financial risk and ensuring a healthy balance between debt and equity in its capital structure.
Coverage ratios
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest coverage | — | 64.56 | 65.56 | 64.04 | -20.75 | -51.74 | -36.25 | -31.88 | -54.09 | -76.66 | -205.06 | -735.39 | -997.13 | -425.32 | -300.92 | -144.09 | -108.85 | -98.77 | -91.27 | -113.83 |
The interest coverage ratio measures a company's ability to meet its interest obligations using its earnings before interest and taxes (EBIT). A higher interest coverage ratio indicates a greater ability to cover interest expenses.
Analyzing the data provided for Protagonist Therapeutics Inc, the interest coverage ratio was negative for most of the reporting periods from March 31, 2020, to September 30, 2022. This indicates that the company's EBIT was insufficient to cover its interest expenses during those periods.
The company experienced a significant improvement in its interest coverage ratio starting from the first quarter of 2024. The ratio turned positive and showed a steady increase in subsequent quarters, reaching 64.04 by March 31, 2024.
This positive trend in the interest coverage ratio suggests that Protagonist Therapeutics Inc's ability to cover its interest expenses has improved. However, it is important to continue monitoring the ratio in future periods to ensure the company's continued financial stability.